Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.2.1 Amendment No. 2 to Warrant to Purchase Shares of Series E Preferred Stock
- 4.3.1 Amendment No. 1 to Warrant to Purchase Shares of Series F Preferred Stock
- 4.3.2 Amendment No. 1 to Warrant to Purchase Shares of Series F Preferred Stock
- 4.8 Form of Series F Original Warrant
- 10.10 Form of Restricted Stock Grant Notice and Restricted Stock Award Agreement
- 10.16 Exclusive Consultancy Agreement Between Ceres, Inc. and Richard Flavell
- 10.25.1 Amendment No. 1 to Line License Agreement
- 10.26.1 Schedule 7 to Master Research Agreement
- 10.31.2 Amendment IV to the Collaboration Agreement
- 23.1 Consent of KPMG LLP
- 31.1 Certification of CEO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 31.2 Certification of CFO Pursuant to Rules 13A-14(A) and 15D-14(A)
- 32.1 Certification of Peo and Pfo Pursuant to Rule 13A-14(B)
Related press release
Cerevel Therapeutics similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of Ceres, Inc.:
We consent to the incorporation by reference in the registration statement No. 333-179739 on Form S-8 of Ceres, Inc. of our report dated November 20, 2012, with respect to the consolidated balance sheets of Ceres, Inc. as of August 31, 2012 and 2011, and the related consolidated statements of operations, comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended August 31, 2012, which report appears in the August 31, 2012 annual report on Form 10-K of Ceres, Inc.
/s/ KPMG LLP
Los Angeles, California
November 20, 2012